Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,118.00
Ask: 12,120.00
Change: 90.00 (0.75%)
Spread: 2.00 (0.017%)
Open: 12,036.00
High: 12,156.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: RBS And Just Eat Slip; Computacenter Climbs

Fri, 26th Apr 2019 08:42

LONDON (Alliance News) - Stock prices in London opened in the red on Friday, with Royal Bank of Scotland slipping after a drop in income and a warning over the impact of Brexit.Elsewhere, Just Eat dipped after a softer than hoped performance in the UK, while Ferrexpo slumped in the FTSE 250 after its auditor quit amid an investigation into charity payments. The FTSE 100 was down 23.81 points, or 0.3%, at 7,410.32 in early trade. The FTSE 250 index was down 11.55 points, or 0.1%, at 19,859.5, while the AIM All-Share was 0.1% higher at 966.The Cboe UK 100 index was down 0.4% at 12,555.53. The Cboe UK 250 was 0.2% at 17,741.84, and the Cboe UK Small Companies was up 0.1% at 11,626.1.On the London Stock Exchange, RBS sat at the bottom of the FTSE 100, down 5.1%, after it reported a decreased profit in the first quarter on lower income and warned Brexit could continue to harm the lender's income growth.The UK government controlled bank's operating pretax profit in the three months ended March decreased 17% to GBP1.01 billion from GBP1.21 billion the year before. RBS's profit attributable to shareholders slipped 13% to GBP707 million.RBS attributed the decreased quarterly profit to lower income.RBS's first quarter total income fell 7.9% to GBP3.04 billion from GBP3.30 billion year-on-year, with net-interest income declining 5.6% to GBP2.03 billion from GBP2.15 billion.The lender's cost-to-income ratio edged up to 63.4% in the quarter compared to 60.5% the year prior. RBS' CET1 ratio at the end of March was 16.2%, down from 16.4% at the end of the first quarter a year ago. At the end of 2018, RBS's CET1 ratio stood at 16.2%.The bank's net interest margin in the first quarter was 1.89% versus 2.04% in the first quarter of 2018. In the fourth quarter of 2018, RBS's NIM was 1.95%."This morning's first quarter update from RBS has been overshadowed somewhat by yesterday's news Chief Executive Ross McEwan will be leaving the business in the next 12 months; however the numbers do illustrate how much the bank has moved on from when he took up the position all the way back in 2013," said CMC Markets UK's Michael Hewson.Online takeaway food platform Just Eat fell 4.2%, as it reported a 21% rise in orders for the first quarter of 2019 to 61.4 million, with revenue up 28% to GBP227.9 million.Just Eat's UK orders rose 7.3% to 31.9 million, but performance was not as good as expected, hurt by a strong comparative, unusually warm weather in February, and the Easter break entirely falling in the second quarter.Outside of the UK, orders surged 40%, helped by strong growth in Canada, Italy, Switzerland, and Ireland.Guidance for 2019 is once again reiterated, with Just Eat seeing revenue between GBP1.0 billion and GBP1.1 billion and underlying earnings before interest, tax, depreciation, and amortisation of GBP185 million to GBP205 million.Miner Glencore slipped 3.4% after reporting late Thursday the US Commodity Futures Trading Commission has launched an investigation into whether the commodities trader has violated provisions of the Commodities Exchange Act.The investigation is currently at an early stage and follows a similar scope to the ongoing investigation by the US Department of Justice. Glencore said it will cooperate with the Commission's investigation.Advertising firm WPP was down 1.0%, despite a slight rise at the open, as it said it is making good progress, with first quarter revenue up 0.9% at reported currency to GBP3.59 billion. Excluding currency movements, revenue was down 0.6%, and like-for-like it fell 1.3%.Like-for-like revenue minus pass-through costs in North America fell 8.5%, making it WPP's weakest performing region, due to continued losses among automotive, pharmaceutical, and fast-moving consumer goods clients.UK like-for-like revenue less pass-through costs fell 0.9%, slightly worse than the year ago period, while the figure fell 0.3% in Western Continental Europe.WPP's like-for-like revenue less pass-through costs elsewhere rose 2.3%, with strong growth in the Latin America, Central & Eastern Europe, and South East Asia segments.WPP has reiterated guidance for 2019, targeting a fall in like-for-like less pass-through costs revenue of 1.5% to 2.0%.AstraZeneca rose just 0.1% as it reported a solid set of first quarter results, with new medicines helping drive growth in product sales.AstraZeneca's product sales climbed 10% for the first three months of 2019 to USD5.47 billion, with constant currency growth 14%. Revenue was up 6%, or 11% constant currency, to USD5.49 billion.Pretax profit doubled to USD758 million, with reported operating profit rising 58% at actual currency rates to USD1.10 billion and core operating profit up 84% at actual rates to USD1.65 billion.Looking within products, Oncology sales rose 54% to USD1.89 billion, New Cardiovascular, Renal, & Metabolism sales rose 15% to USD1.03 billion, and Respiratory sales climbed 9% to USD1.28 billion.pressure.Emerging markets as a segment posted 14% growth to USD2.00 billion, with Chinese sales up 21%.Looking ahead, AstraZeneca has reiterated all 2019 guidance, including for high single-digit growth in product sales.In the FTSE 250, Computacenter surged 12%, with first-quarter revenue and profit ahead year-on-year, before the "positive" impact of acquisitions. This is above expectations, given a tough comparative year-on-year.The UK saw revenue growth despite a large one-off deal a year prior, while US also achieved revenue growth on a like-for-like basis.Looking ahead, Computacenter is "firmly" on track to meet 2019 expectations, and confidence has increased following the first quarter performance.Stagecoach also rose, climbing 3.8%, after Citigroup raised its rating on the stock to Buy from Neutral. Iron ore pellet maker Ferrexpo slumped 14%. Auditor Deloitte has resigned with immediate effect, the company announced.The company recently published long-delayed 2018 results amid an investigation into payments to a charity in Ukraine.Insurer Hastings fell 5.1%, reporting a 4% rise in gross written premiums to GBP235.5 million for the first quarter, with live customer policies up 3% to 2.75 million. Net revenue fell 1% to GBP183.1 million.Looking ahead, Hastings said if current market premium and claims dynamics continue through the remainder its loss ratio for 2019 will be towards the upper end of its 75% to 79% target range.Hastings also confirmed new Chief Financial Officer John Worth will join on May 10.Wall Street ended mixed in the US on Thursday following the continuation of its own earnings season, with the Dow Jones Industrial Average closing 0.5% lower, the S&P 500 marginally lower, but the Nasdaq Composite up 0.2%.SPI Asset Management's Steve Innes said: "US markets traded mixed as the latest earnings reports sent investors scurrying every which way but higher as big tech heavyweight gains were neutralised by industrial stalwarts whose sector shares tracked lower."But adding to top side pressures is the uniform move covering a breadth of cross-asset markets which suggest investors are starting to weave yet another cautionary tale as global growth concern continue to mount."The Japanese Nikkei 225 index ended down 0.3% Friday. In China, the Shanghai Composite closed 0.8% down, while the Hang Seng index in Hong Kong is flat in late trade. The economic calendar has UK BBA mortgage approval figures at 0930 BST and US first-quarter GDP at 1330 BST."Economists are expecting a reading of 2.1%. The figure will be closely watched as the Federal Reserve lowered its growth forecast for 2019 to 2.1%, from the 2.3% projection in December," said CMC Markets UK's David Madden."The US central bank have dropped a big hint interest rates are likely to hold steady for the foreseeable future, but they have also given themselves the wiggle room for a hike, should the economy outperform."

More News
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more
6 Sep 2023 07:45

AstraZeneca working with FDA on finer details of Ultomiris treatment

(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).

Read more
4 Sep 2023 15:46

UK dividends calendar - next 7 days

Tuesday 5 September 
no events scheduled 
Wednesday 6 September 
no events scheduled 
Thursday 7 September 
Admiral Group PLCex-dividend payment date
Alpha Financial Markets Consulting PLCex-dividend payment date
Anglo-Eastern Plantations PLCex-dividend payment date
Assura PLCex-dividend payment date
Athelney Trust PLCex-dividend payment date
Baltic Classifieds Group PLCex-dividend payment date
Blackrock World Mining Trust PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
CT UK Capital & Income Investment Trust PLCex-dividend payment date
Derwent London PLCex-dividend payment date
Develop North PLCex-dividend payment date
DS Smith PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Greggs PLCex-dividend payment date
Harbour Energy PLCex-dividend payment date
Pollen Street PLCex-dividend payment date
Prudential PLCex-dividend payment date
Relx PLCdividend payment date
RM Infrastructure Income PLCex-dividend payment date
Serco Group PLCex-dividend payment date
Severfield PLCex-dividend payment date
VPC Specialty Lending Investments PLCex-dividend payment date
XP Power Ltdex-dividend payment date
Zotefoams PLCex-dividend payment date
Friday 8 September 
abrdn New Dawn Investment Trust PLCdividend payment date
Avon Protection PLCdividend payment date
Berkeley Group Holdings PLCdividend payment date
Chemring Group PLCdividend payment date
Ecofin US Renewables Infrastructure Trust PLCdividend payment date
iomart Group PLCdividend payment date
Keller Group PLCdividend payment date
Lookers PLCdividend payment date
Moneysupermarket.com Group PLCdividend payment date
Nichols PLCdividend payment date
Tritax EuroBox PLCdividend payment date
Tyman PLCdividend payment date
Monday 11 September 
AstraZeneca PLCdividend payment date
Games Workshop Group PLCdividend payment date
Rentokil Initial PLCdividend payment date
Residential Secure Income PLCdividend payment date
ThomasLloyd Energy Impact Trust PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
4 Sep 2023 12:13

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

Read more
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.